Pay in 4 interest-free payments of $5.05 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
This separates it from peptide-based research compounds such as Semaglutide, Tirzepatide, Retatrutide, and Cagrilintide
Structural basis for alginate secretion across the bacterial outer membrane
Evaluating rezatapopt*, a first-in-class p53 reactivator, as a treatment for TP53 Y220Cmutant locally advanced and metastatic solid tumours The experts discuss: TP53 Y220C mutation and rationale for targeted therapy Study overview and practice implications, spotlighting ovarian cancer Testing strategies for early and accurate patient identification Video in this post *Rezatapopt is an investigational agent which is not approved by a regulatory agency This programme has been sponsored by PMV Pharma #MedicalEducation #Oncology Update from AACRNCIEORTC 2025: PYNNACLE Phase 2 evaluating rezatapopt in TP53 Y220Cmutant solid tumours To view or add a comment, sign in 26,264 followers
THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE
Our trained paramedics and registered nurses bring IV therapy to your location, so you can benefit from a Myers' Cocktail infusion without leaving the comfort of your home or hotel room
